90 related articles for article (PubMed ID: 17122103)
1. Biological effects of thyrotropin receptor activation on human orbital preadipocytes.
Zhang L; Baker G; Janus D; Paddon CA; Fuhrer D; Ludgate M
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5197-203. PubMed ID: 17122103
[TBL] [Abstract][Full Text] [Related]
2. TSH stimulates adipogenesis in mouse embryonic stem cells.
Lu M; Lin RY
J Endocrinol; 2008 Jan; 196(1):159-69. PubMed ID: 18180327
[TBL] [Abstract][Full Text] [Related]
3. Adipose-specific inactivation of thyroid stimulating hormone receptors in mice modifies body weight, temperature and gene expression in adipocytes.
Lundbäck V; Kulyté A; Dahlman I; Marcus C
Physiol Rep; 2020 Aug; 8(16):e14538. PubMed ID: 32812397
[TBL] [Abstract][Full Text] [Related]
4. Enhanced orbital adipogenesis in a mouse model of T-cell-mediated autoimmunity, zymosan A-treated SKG mice: Implications for Graves' ophthalmopathy.
Park S; Park DY; Kim J; Woo KI; Kim YD; Han J; Chung TY; Cha HS; Lim DH
Sci Rep; 2020 Apr; 10(1):7329. PubMed ID: 32355208
[TBL] [Abstract][Full Text] [Related]
5. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.
Krieger CC; Boutin A; Jang D; Morgan SJ; Banga JP; Kahaly GJ; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Endocrinology; 2019 Jun; 160(6):1468-1479. PubMed ID: 31127272
[TBL] [Abstract][Full Text] [Related]
6. Neuronostatin regulates proliferation and differentiation of rat brown primary preadipocytes.
Krążek M; Wojciechowicz T; Fiedorowicz J; Strowski MZ; Nowak KW; Skrzypski M
FEBS Lett; 2024 May; ():. PubMed ID: 38794908
[TBL] [Abstract][Full Text] [Related]
7. Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves' orbitopathy: clinical implications.
Pawlowski P; Reszec J; Eckstein A; Johnson K; Grzybowski A; Chyczewski L; Mysliwiec J
Mediators Inflamm; 2014; 2014():412158. PubMed ID: 25309050
[TBL] [Abstract][Full Text] [Related]
8. A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit.
Zhang M; Ding X; Wu LP; He MQ; Chen ZY; Shi BY; Wang Y
Thyroid; 2021 Apr; 31(4):638-648. PubMed ID: 33076782
[No Abstract] [Full Text] [Related]
9. The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Moledina M; Damato EM; Lee V
Eye (Lond); 2024 Jun; 38(8):1425-1437. PubMed ID: 38374366
[TBL] [Abstract][Full Text] [Related]
10. Pituitary crosstalk with bone, adipose tissue and brain.
Zaidi M; Yuen T; Kim SM
Nat Rev Endocrinol; 2023 Dec; 19(12):708-721. PubMed ID: 37715028
[TBL] [Abstract][Full Text] [Related]
11. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
[TBL] [Abstract][Full Text] [Related]
12. Unexpected Crosslinking Effects of a Human Thyroid Stimulating Monoclonal Autoantibody, M22, with IGF1 on Adipogenesis in 3T3L-1 Cells.
Umetsu A; Sato T; Watanabe M; Ida Y; Furuhashi M; Tsugeno Y; Ohguro H
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674625
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
14. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
15. Orbital Signaling in Graves' Orbitopathy.
Draman MS; Zhang L; Dayan C; Ludgate M
Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
[TBL] [Abstract][Full Text] [Related]
16. Expression of Endogenous Putative TSH Binding Protein in Orbit.
Draman MS; Grennan-Jones F; Taylor P; Muller I; Evans S; Haridas A; Morris DS; Rees DA; Lane C; Dayan C; Zhang L; Ludgate M
Curr Issues Mol Biol; 2021 Oct; 43(3):1794-1804. PubMed ID: 34889904
[TBL] [Abstract][Full Text] [Related]
17. The Role of Mitochondria-Linked Fatty-Acid Uptake-Driven Adipogenesis in Graves Orbitopathy.
Zhang L; Rai P; Miwa S; Draman MS; Rees DA; Haridas AS; Morris DS; Tee AR; Ludgate M; Turnbull DM; Dayan CM
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34473251
[TBL] [Abstract][Full Text] [Related]
18. Distinctive Features of Orbital Adipose Tissue (OAT) in Graves' Orbitopathy.
Zhang L; Evans A; von Ruhland C; Draman MS; Edkins S; Vincent AE; Berlinguer-Palmini R; Rees DA; Haridas AS; Morris D; Tee AR; Ludgate M; Turnbull DM; Karpe F; Dayan CM
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266331
[TBL] [Abstract][Full Text] [Related]
19. Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
Kahaly GJ
J Clin Endocrinol Metab; 2020 Dec; 105(12):3704-20. PubMed ID: 32929476
[TBL] [Abstract][Full Text] [Related]
20. Fibrosis in dysthyroid eye disease.
Ludgate M
Eye (Lond); 2020 Feb; 34(2):279-284. PubMed ID: 31844169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
